Summit Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-2,788
Closed -$208K 156
2021
Q3
$208K Buy
2,788
+52
+2% +$4.36K 0.07% 145
2021
Q2
$253K Sell
2,736
-975
-26% -$82.9K 0.08% 132
2021
Q1
$329K Buy
3,711
+492
+15% +$48.8K 0.11% 107
2020
Q4
$300K Sell
3,219
-60
-2% -$4.78K 0.11% 109
2020
Q3
$209K Buy
+3,279
New +$192K 0.09% 122

Other funds holding ARKG

Summit Asset Management's ARKG Position: Q4 2021 in Review

Summit Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 2,788 shares — an estimated $208K sold.

Summit Asset Management first reported a position in ARKG in Q3 2020 and held it in 5 quarters. The position peaked at $329K in Q1 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Summit Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Summit Asset Management sold 2,788 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $208K.
  • Summit Asset Management first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 5 quarters.
  • Summit Asset Management's ARK Genomic Revolution ETF position peaked at $329K in Q1 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Summit Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.